Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?

With the caveat that we do not have level I evidence specifically for this clinical scenario yet (ongoing NeoADAURA study may potentially provide some answers in the future), based on very favorable outcomes of patients with NSCLC in general who derived pathologic complete response after neoadjuvant...

The adequacy of adjuvant therapy, especially when pathological complete response (pCR) is achieved, remains to be determined. Although pathologic complete response (pCR) is a favorable surrogate indicator, the achievement of pCR does not guarantee the absence of viable tumor cells. (Hellmann et al.,...